These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31385309)

  • 21. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
    J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
    Drandi D; Kubiczkova-Besse L; Ferrero S; Dani N; Passera R; Mantoan B; Gambella M; Monitillo L; Saraci E; Ghione P; Genuardi E; Barbero D; Omedè P; Barberio D; Hajek R; Vitolo U; Palumbo A; Cortelazzo S; Boccadoro M; Inghirami G; Ladetto M
    J Mol Diagn; 2015 Nov; 17(6):652-60. PubMed ID: 26319783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
    Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
    Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
    Klener P; Fronkova E; Kalinova M; Belada D; Forsterova K; Pytlik R; Blahovcova P; Simkovic M; Salek D; Mocikova H; Prochazka V; Janikova A; Vaskova M; Mejstrikova E; Kodet R; Trka J; Trneny M
    Hematol Oncol; 2018 Dec; 36(5):773-778. PubMed ID: 30129045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
    Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
    Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum BCL2/IGH DNA in follicular lymphoma patients: a minimal residual disease marker.
    Gocke CD; Kopreski MS; Benko FA; Sternas L; Kwak LW
    Leuk Lymphoma; 2000 Sep; 39(1-2):165-72. PubMed ID: 10975396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
    König L; Dreyling M; Dürig J; Engelhard M; Hohloch K; Viardot A; Witzens-Harig M; Kieser M; Klapper W; Pott C; Herfarth K
    Trials; 2019 Aug; 20(1):544. PubMed ID: 31470902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
    Böttcher S; Stilgenbauer S; Busch R; Brüggemann M; Raff T; Pott C; Fischer K; Fingerle-Rowson G; Döhner H; Hallek M; Kneba M; Ritgen M
    Leukemia; 2009 Nov; 23(11):2007-17. PubMed ID: 19641522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice.
    Janikova A; Mareckova A; Dvorakova D; Bortlicek Z; Tichy B; Navratil M; Kral Z; Pospisilova S; Mayer J
    Exp Hematol; 2012 Jul; 40(7):528-539.e4. PubMed ID: 22381682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does MRD have a role in the management of iNHL?
    Giudice ID; Starza ID; Foà R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy.
    Pulsoni A; Starza ID; Frattarelli N; Ghia E; Carlotti E; Cavalieri E; Matturro A; Tempera S; Rambaldi A; Foà R
    Br J Haematol; 2007 May; 137(3):216-20. PubMed ID: 17408460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.
    Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL
    J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
    Jia YP; Liu GL; Zhang LP
    Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal?
    Mondello P; Steiner N; Wasle I; Pitini V; Mian M
    Anticancer Res; 2014 Nov; 34(11):6701-4. PubMed ID: 25368277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
    Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
    Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible influence of clinical stage and type of treatment in the persistence of residual circulating t(14;18)-positive cells in follicular lymphoma patients.
    Colleoni GW; Duarte LC; Kerbauy FR; Noguti MA; Felix RS; De Oliveira JS; Figueiredo MS; Alves AC
    Leuk Lymphoma; 2004 Mar; 45(3):539-45. PubMed ID: 15160916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.